Inovio自主开发前列腺癌的免疫治疗;将继续保持与罗氏合作乙

StephenW

Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy

Inovio Pharmaceuticals.

PLYMOUTH MEETING, Pa., Nov. 17, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the company and Roche have terminated their 2013 collaboration, option, and license agreement to co-develop INO-5150, Inovio's DNA immunotherapy targeting prostate cancer, as well as their research collaboration in prostate cancer. All of Roche's rights to INO-5150, including the right to license the product to other parties, will be returned to Inovio.  Inovio plans to independently advance INO-5150 into a phase I clinical trial in the first half of 2015.

Inovio and Roche will continue to collaborate and co-develop Inovio's DNA immunotherapy (INO-1800) against hepatitis B virus under their existing license agreement. The partnership is on track to move INO-1800 collaboratively into a phase I study in 2015.

Dr. J. Joseph Kim, Inovio's president & CEO, said, "The Inovio/Roche partnership will continue to thrive focusing on the development of INO-1800 for the treatment of hepatitis B. In addition to recently demonstrating clinical efficacy and the ability to induce potent antigen specific CD8+ T cell responses in our VGX-3100 phase II study, Inovio will be moving a broad portfolio of immuno-oncology products through development, including INO-3112 (head/neck and cervical cancers), INO-1400 (breast, lung and pancreatic cancers) and INO-5150 (prostate cancer). We believe that these products along with pre-phase III VGX-3100 will further our growth and represent opportunities for additional value-adding partnerships."

About INO-5150 for Prostate Cancer
Inovio's dual-antigen synthetic DNA immunotherapy (INO-5150) targets prostate-specific membrane antigen (PSMA) and prostate-specific antigen (PSA). A study in monkeys showed that vaccination with INO-5150 generated strong and robust T-cell immune responses that were the highest generated by a PSA-targeting immunotherapy in animal studies and were similar to the immune responses generated by VGX-3100, Inovio's phase II-completed HPV immunotherapy that generated best-in-class T-cell responses.

Inovio's SynCon® DNA vaccine for prostate cancer was designed with PSA and PSMA synthetic consensus immunogens based on human and macaque sequences, resulting in amino acid sequences that differ slightly from the native human protein. In humans, this novel approach is utilized to help the body's immune system recognize cancerous cells created in the body as 'foreign', overcoming the body's self-tolerance of these cells and mounting an immune response to clear them.

About INO-1800 for Hepatitis B
Inovio has reported preclinical data showing its hepatitis B vaccine (INO-1800) generated strong T-cell and antibody responses that led to the elimination of targeted liver cells in mice. These results indicate this DNA immunotherapy's potential to treat hepatitis B infection and prevent further development of the infection into liver cancer in humans.

In a preclinical study, researchers found the vaccine-specific T-cells exhibited a killing function, and could migrate to and stay in the liver and cause clearance of target cells without evidence of liver injury. This was the first study to provide evidence that intramuscular immunization can induce killer T-cells that can migrate to the liver and eliminate target cells.

About Inovio

Inovio is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of cancer immunotherapies and clinical studies, the company is advancing a growing product pipeline. Partners and collaborators include Roche, MedImmune, the University of Pennsylvania, DARPA, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, US Dept. of Homeland Security, and University of Manitoba. For more information, visit www.inovio.com.

StephenW

Inovio制药公司自主开发前列腺癌的免疫治疗;将继续保持合作，并许可与罗氏公司Inovio的乙肝免疫治疗协议

Inovio制药公司。

普利茅斯会议，宾夕法尼亚州，2014年11月17日/新华美通/ -  Inovio制药公司（纳斯达克股票代码：INO）今天宣布，该公司与罗氏公司已经终止了2013协作，选项和许可协议，以共同开发INO-5150 ，Inovio的DNA靶向免疫治疗前列腺癌，以及前列腺癌的研究合作。所有罗氏的权利INO-5150，包括许可的产品给其他方的权利，将返回到Inovio。 Inovio计划独立推进INO-5150进入I期临床试验中的第一个2015年的一半。

Inovio和罗氏将继续合作，共同开发下，现有的许可协议Inovio的DNA免疫（INO-1800）抗乙肝病毒。这种伙伴关系的轨道上移动INO-1800协作为我研究在2015年的一个阶段。

J.博士约瑟夫·金，Inovio公司的总裁兼首席执行官说：“Inovio/罗氏的合作伙伴关系将继续蓬勃发展重点INO-1800的开发乙型肝炎另外的治疗，最近表现出的临床疗效和能力引起我们的VGX-3100 II期临床研究有效的抗原特异性CD8+ T细胞应答，Inovio将通过发展来移动的免疫肿瘤产品的广泛产品组合，其中包括INO-3112（头/颈部和子宫颈癌），INO-1400（乳房，肺癌和胰腺癌）和INO-5150（前列腺癌）。我们相信，这些产品与前三期VGX-3100将进一步推动我们的增长，代表了额外的增值伙伴关系的机会。“

关于INO-5150前列腺癌
Inovio的双抗原合成DNA免疫（INO-5150）针对前列腺特异性膜抗原（PSMA）和前列腺特异性抗原（PSA）。在猴中的研究表明，接种INO-5150产生的强和健壮的T细胞免疫反应是通过在动物研究中的粘合剂靶向免疫治疗所产生的最高和类似于由VGX-3100，Inovio的第二阶段中产生的免疫应答-completed HPV免疫生成最佳的类T细胞应答。

Inovio的SynCon®DNA疫苗对前列腺癌的设计采用了PSA和PSMA的合成免疫原的共识基于人和猕猴序列，导致从天然人蛋白略有不同的氨基酸序列。在人类中，这种新方法被用来帮助身体的免疫系统识别为“外来”在体内产生癌性细胞，克服身体的自身耐受这些细胞和产生免疫应答，以清除它们。

关于INO-1800 B型肝炎
Inovio报告临床数据显示其乙肝疫苗（INO-1800）产生了浓厚的T细胞和抗体反应，导致了有针对性的消除肝细胞的小鼠。这些结果表明这种DNA免疫治疗的潜在治疗乙肝感染，防止感染进一步发展成肝癌的人。

在临床前研究中，研究人员发现了疫苗特异性T细胞表现出杀伤作用，并能迁移到并留在靶细胞中的肝和原因的间隙而不肝损伤的证据。这是第一次研究提供的证据表明，肌内免疫接种可诱导杀伤T细胞，它可以迁移到肝脏和消除靶细胞。

关于Inovio

Inovio是革命性的对抗癌症和传染病的斗争。我们的免疫疗法独特地激活最好的一流的免疫应答，以预防和治疗疾病，并且已经表明在临床显著功效具有良好的安全性。癌症免疫治疗和临床研究的不断扩大产品组合，公司正在推进越来越多的产品线。合作伙伴和合作者包括罗氏，MedImmune公司，宾夕法尼亚大学，DARPA，德雷塞尔大学，美国国立卫生研究院，HIV疫苗试验网络，美国国家癌症研究所，美国军方艾滋病研究计划，美国国土安全部和马尼托巴大学。欲了解更多信息，请访问www.inovio.com。

MP4

罗氏也开始搞治疗性疫苗了